246 related articles for article (PubMed ID: 23324246)
21. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas.
Saggiorato E; Aversa S; Deandreis D; Arecco F; Mussa A; Puligheddu B; Cappia S; Conticello S; Papotti M; Orlandi F
J Endocrinol Invest; 2004 Apr; 27(4):311-7. PubMed ID: 15233548
[TBL] [Abstract][Full Text] [Related]
22. Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature.
Dunđerović D; Lipkovski JM; Boričic I; Soldatović I; Božic V; Cvejić D; Tatić S
Diagn Pathol; 2015 Oct; 10():196. PubMed ID: 26503236
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19.
Murtezaoglu AR; Gucer H
Pol J Pathol; 2017; 68(1):1-10. PubMed ID: 28547974
[TBL] [Abstract][Full Text] [Related]
24. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms.
Inohara H; Honjo Y; Yoshii T; Akahani S; Yoshida J; Hattori K; Okamoto S; Sawada T; Raz A; Kubo T
Cancer; 1999 Jun; 85(11):2475-84. PubMed ID: 10357421
[TBL] [Abstract][Full Text] [Related]
25. Papillary thyroid tumors: Diagnostic value of CD56 and Cytokeratin 19.
Zehani A; Bani A; Chelly I; Rejaibi S; Besbes G; Haouet S; Kchir N
Tunis Med; 2018 Feb; 96(2):113-121. PubMed ID: 30324976
[TBL] [Abstract][Full Text] [Related]
26. Challenge in the Pathological Diagnosis of the Follicular- Patterned Thyroid Lesions.
Elsers DA; Hussein MRA; Osman MH; Mohamed GA; Hosny G
Asian Pac J Cancer Prev; 2021 Oct; 22(10):3365-3376. PubMed ID: 34711014
[TBL] [Abstract][Full Text] [Related]
27. Ultrasound Risk Assessment Combined with Molecular Markers of Galectin-3, c-MET, HBME-1 and CK19 for Diagnosis of Malignant and Benign Thyroid Nodules.
Han RL; Wang J; Zhang FJ; Zhao N; Gao BL
Pathol Oncol Res; 2019 Jul; 25(3):1075-1081. PubMed ID: 30361909
[TBL] [Abstract][Full Text] [Related]
28. [Expression of Twist in papillary thyroid carcinomas and its roles in differential diagnosis].
He CN; He L; Cheng JQ; Chen SC; Zhao HF; Zhai JP; Zhang J
Zhonghua Bing Li Xue Za Zhi; 2008 Jan; 37(1):35-9. PubMed ID: 18509983
[TBL] [Abstract][Full Text] [Related]
29. In Situ Hybridization Analysis of miR-146b-5p and miR-21 in Thyroid Nodules: Diagnostic Implications.
Guo Z; Hardin H; Montemayor-Garcia C; Asioli S; Righi A; Maletta F; Sapino A; Lloyd RV
Endocr Pathol; 2015 May; 26(2):157-63. PubMed ID: 25771986
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.
Park YJ; Kwak SH; Kim DC; Kim H; Choe G; Park DJ; Jang HC; Park SH; Cho BY; Park SY
J Korean Med Sci; 2007 Aug; 22(4):621-8. PubMed ID: 17728499
[TBL] [Abstract][Full Text] [Related]
31. HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma.
Nga ME; Lim GS; Soh CH; Kumarasinghe MP
Diagn Cytopathol; 2008 Aug; 36(8):550-6. PubMed ID: 18618720
[TBL] [Abstract][Full Text] [Related]
32. Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules.
Saleh HA; Jin B; Barnwell J; Alzohaili O
Diagn Pathol; 2010 Jan; 5():9. PubMed ID: 20181018
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma.
Chen YJ; Zhao RM; Zhao Q; Li BY; Ma QY; Li X; Chen X
Tumour Biol; 2016 Jul; 37(7):8715-20. PubMed ID: 26738867
[TBL] [Abstract][Full Text] [Related]
34. [HBME-1 immunostaining in thyroid pathology].
Rigau V; Martel B; Evrard C; Rousselot P; Galateau-Salle F
Ann Pathol; 2001 Feb; 21(1):15-20. PubMed ID: 11223556
[TBL] [Abstract][Full Text] [Related]
35. [Comparison of CD15, galectin-3 and HBME-1 expression in follicular thyroid neoplasms].
Bogdańska M; Górnicka B; Ziarkiewicz-Wróblewska B; Koperski L; Morton M; Wasiutyński A
Endokrynol Pol; 2006; 57(4):314-9. PubMed ID: 17006830
[TBL] [Abstract][Full Text] [Related]
36. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.
Saggiorato E; De Pompa R; Volante M; Cappia S; Arecco F; Dei Tos AP; Orlandi F; Papotti M
Endocr Relat Cancer; 2005 Jun; 12(2):305-17. PubMed ID: 15947105
[TBL] [Abstract][Full Text] [Related]
37. The absence of CD56 expression can differentiate papillary thyroid carcinoma from other thyroid lesions.
Golu I; Vlad MM; Dema A; Moleriu LC; Tudor A; Iacob M; Popa O; Cornianu M
Indian J Pathol Microbiol; 2017; 60(2):161-166. PubMed ID: 28631628
[TBL] [Abstract][Full Text] [Related]
38. [Usefulness of CK19, HBME-1 and galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions].
Tong J; Wang Y; Da JP
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):599-604. PubMed ID: 22325220
[TBL] [Abstract][Full Text] [Related]
39. Molecular classification of thyroid nodules by cytology.
Pagedar NA; Chen DH; Wasman JK; Savvides P; Schluchter MD; Wilhelm SM; Lavertu P
Laryngoscope; 2008 Apr; 118(4):692-6. PubMed ID: 18094649
[TBL] [Abstract][Full Text] [Related]
40. [Diagnosis of the follicular variant of papillary thyroid carcinoma. Significance of immunohistochemistry].
Guyétant S; Michalak S; Valo I; Saint-André JP
Ann Pathol; 2003 Feb; 23(1):11-20. PubMed ID: 12743496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
